Question 1

What is the recommended dosing for SS-31 peptide?

Accepted Answer

There is no recommended amount for SS-31, and that is a fact about the regulatory record rather than a dodge. Elamipretide has a single approval, and its wording is narrow: elamipretide is indicated for the improvement of muscle strength in individuals with Barth syndrome. That approval covers elamipretide as an approved product in that one disease. It does not transfer to material sold as SS-31, or to any other use or population, and none of the sources cited on this page reproduces the amount on that label. Outside it, what exists is a decade of registered trials in rare inherited disease. One figure keeps coming back, and it is 40 mg a day, under the skin. In the phase 3 MMPOWER-3 trial, eligible participants were randomized 1:1 to receive either 24 weeks of elamipretide at a dose of 40 mg/d or placebo subcutaneously. In the Barth syndrome work that followed, patients entering the open-label extension continued elamipretide 40 mg subcutaneous daily. Both of those are trial protocols, each written by investigators for one supervised group of patients, using material of known identity and strength. Reporting a protocol is not the same act as handing somebody a schedule, and neither trial set out to establish a suitable amount for anybody outside it.

Question 2

What is actually on an SS-31 peptide dosage chart?

Accepted Answer

Charts circulating under this name usually show a ladder of weekly amounts with a cycle length printed beside them, arranged as though a single sequence applied to everyone. The published record holds nothing of that shape at all. What it holds is two daily figures from two trials in two unrelated inherited conditions. MMPOWER-3 randomised 218 adults, 109 to elamipretide and 109 to placebo, in primary mitochondrial myopathy, a group of genetic disorders that impair mitochondrial oxidative phosphorylation, which is the process cells use to turn fuel into usable energy. The Barth syndrome work was a 28-week randomized, double-blind, and placebo-controlled trial followed by a 168-week open-label extension. An honest chart built from those two lines would carry two rows, each labelled with the rare disease it came from. Anything longer has been assembled from somewhere other than the published trial record. A figure that no study covered here supports tells a reader about whoever typed it rather than about the compound, and it cannot be checked against anything.

Question 3

How much SS-31 was given per day?

Accepted Answer

Per day is the right unit for the published human work, because both trials that report an amount gave it once daily rather than weekly. One ran 40 mg a day for 24 weeks against placebo, and the extension study continued the same 40 mg daily for a further 168 weeks. Whether a larger amount would do more has been examined once, indirectly, and the signal was faint. A later analysis of the same trial showed a weak positive correlation between plasma elamipretide concentration and 6MWT improvement, where the 6MWT is a six-minute walking test used as a measure of exercise capacity. Read the weight of that carefully. The parent trial did not meet its primary endpoints assessing changes in the 6MWT and PMMSA total fatigue score, the two things it was built to measure. A correlation found inside a subgroup of a trial that missed its own endpoints is a reason to be careful with the number rather than a reason to raise it.

Question 4

How was SS-31 administered, and by what route?

Accepted Answer

Under the skin, in every human trial that reports an amount, and the choice of route was not a free one. A 2023 study in mice notes that elamipretide is a short tetrameric peptide that is not orally bioavailable, limiting its routes of administration. In plain terms, swallowing it does not work. The registered trials then split by target organ. One phase 1 study gave Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration, an eye disease of ageing. A separate line of eye work used an Elamipretide Topical Ophthalmic Solution instead, which is to say eye drops rather than a needle. The heart work took place on a hospital ward. Blood was obtained from patients (n=19) after a first heart attack, and 10 of the patients received the mitochondria-targeting peptide elamipretide. No trial among the research behind this page has compared one route against another, so the registered record shows which routes were used rather than which one delivers more of the compound where it is intended to act.

Question 5

How long did people stay on SS-31 in the trials?

Accepted Answer

Two published answers exist and they are a long way apart. The myopathy trial ran 24 weeks of elamipretide at a dose of 40 mg/d or placebo subcutaneously, which is a little under six months of daily injections. The Barth syndrome work ran far longer, through a 168-week open-label extension in which everyone involved knew they were receiving the compound. Ten patients entered the OLE; 8 reached the week 168 visit, so the longest human exposure on record rests on eight people with an inherited disorder of heart and muscle, none of them blinded to what they were taking. How quickly anything changes is a separate question, and neither trial was built to answer it. Both assessed participants at fixed visits, so they report where a group stood at week 24 or week 168 rather than the week in which a difference first appeared. Anyone quoting a time to effect for this compound is quoting something the published schedule of assessments cannot show.

Question 6

What amounts were used in the heart studies?

Accepted Answer

The heart trials are where the largest exposures are described, and they are also the place where the published numbers stop. A 2022 review states that in early-phase clinical trials, elamipretide administration has not resulted in any severe adverse events. The same sentence adds that the gains in blood flow through the heart came at highest doses. That phrase is as close to a figure as the sentence gets. The registered study behind it looked at the Cardiac and Renal Effects of Short Term Treatment With Elamipretide, and its entry lists no amount at all. The earlier heart-attack work is smaller still, and it reported a blood marker rather than a schedule. In that study elamipretide significantly reduced the HtrA2 median serum level after myocardial infarction in the ten treated patients. One hospital admission, a single blood marker, and no amount anywhere in the published report is the whole of what is available.

Question 7

Is there an amount for performance, bodybuilding or healthy ageing?

Accepted Answer

Not in people, and the gap is worth stating precisely. The published work on exercise capacity in ageing is entirely in animals, and it is specific about frequency while staying silent on quantity. A 2023 study tested whether twice weekly intermittent injections of elamipretide could match the same gains as continuous long-term infusion. It ran for eight months, which is a large slice of a mouse life. The authors found that intermittent treatment with elamipretide for 8 months preserved exercise tolerance and left ventricular mass in mice. Kidney function did not follow, as it had under the continuous schedule. Notice what was actually being compared: two injection schedules set against each other in aged female mice, rather than an amount against a person. The experiment names a frequency and a duration and no quantity at all, so there is no figure inside it that could be carried anywhere. A phase 2 Study of Healthy Aging and Physical Function With Elamipretide is listed as RECRUITING and has published nothing.

Question 8

Is SS-31 cycled, and is there an off period?

Accepted Answer

No trial among the research behind this page has tested a break, a taper or a repeat course, so there is no cycle length available to report. What the record contains instead is uninterrupted daily administration for as long as each trial lasted, which was 24 weeks in the myopathy study and a further 168 weeks in the extension that followed the Barth syndrome trial. The nearest anyone has come to a cycling question was asked in mice, and it was asked about frequency rather than about stopping. The ageing study compared twice weekly intermittent injections of elamipretide against continuous long-term infusion over eight months. That is a comparison between two uninterrupted schedules rather than between using something and pausing it. No study among the research behind this page has published what happens when a course ends, whether anything persists, fades or rebounds, which means the cycling question has not been asked rather than answered and found wanting.

Question 9

How long should SS-31 be taken before MOTS-c?

Accepted Answer

No study among the research behind this page has given SS-31 and MOTS-c together in any order, at any interval, in any species. There is no sequencing information because there is no combination information, and the two compounds have never appeared inside the same published protocol. What can be said is what each record separately contains. In MMPOWER-3 the only comparison was elamipretide against placebo, with no second compound in either arm of the trial. That isolation is the point of the design, because a second compound arriving on a schedule of its own would make any result impossible to attribute. So the question is being put to a literature that never addressed it, and the honest answer is a description of that silence rather than a number of weeks. Our comparison page sets out what each of the two compounds has actually been studied for, which is a different question from the order anybody might use them in.

Question 10

How much bacteriostatic water goes into a 10 mg vial of SS-31?

Accepted Answer

That is arithmetic, and it is one of the few questions on this page with a definite answer. A 10 mg vial holds 10,000 micrograms whatever volume is added to it, and the diluent only decides the concentration that results. One millilitre of bacteriostatic water produces 10,000 mcg/mL, two millilitres produces 5,000 mcg/mL, and five millilitres produces 2,000 mcg/mL. On a U-100 insulin syringe every unit mark is one hundredth of a millilitre, so at 5,000 mcg/mL a single mark holds 50 micrograms and ten marks hold 500 micrograms. Those are conversions between units and they hold whatever anybody decides to draw. What the arithmetic cannot supply is the figure to aim at, and the scale of the published trials makes that point sharply. Participants received elamipretide at a dose of 40 mg/d or placebo subcutaneously, which is four times the entire contents of a 10 mg vial every single day, under supervision, for a diagnosed inherited disease.

Question 11

How do mg, mcg and syringe units line up?

Accepted Answer

One milligram is a thousand micrograms, so a 10 mg vial holds 10,000 mcg and a 50 mg vial holds 50,000 mcg. Milligrams measure the compound itself while millilitres measure the liquid it has been dissolved in, and the two quantities are unrelated until a diluent volume has been chosen. Concentration is the bridge between them: the total micrograms divided by the millilitres of diluent gives micrograms per millilitre. A U-100 insulin syringe is marked in units rather than in volume, and since one hundred units make a millilitre, each mark carries a hundredth of a millilitre of whatever concentration was mixed. The published trial figures arrive in milligrams per day rather than in syringe units, so moving between the two is arithmetic rather than interpretation. Our reconstitution and conversion tools will run these sums on the numbers you enter, and neither of them proposes a target amount, because no established target exists to propose.

Question 12

Why is there still no established amount after a decade of trials?

Accepted Answer

An amount becomes established when a regulator approves a product at that amount for a stated indication, and that has happened once, for one disease. In 2025 elamipretide became the first disease-specific treatment approved for Barth syndrome. That label belongs to the approved product in that disease and establishes nothing for SS-31 bought elsewhere or for anyone else. The largest trial in the programme, registered as a study of the Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy, now carries the status TERMINATED on the public registry. Its own conclusion is blunt. The trial provides Class I evidence that elamipretide does not improve the 6MWT or fatigue at 24 weeks compared with placebo in patients with primary mitochondrial myopathy. A later analysis of the same participants found a signal in one genetic subgroup. Those data serve as the foundation for a follow-up Phase 3 clinical trial in patients who share that profile. That is how a development programme continues after a negative result, and it is also why the one repeated human figure on this page is still 40 mg a day, taken from trial protocols rather than from the Barth syndrome label.

Question 13

Why do the published amounts and routes vary?

Accepted Answer

They vary considerably less than the circulating charts imply, and where they do differ it tracks the organ under investigation rather than any hunt for an optimum. The muscle trial and the Barth syndrome extension both landed on 40 mg daily under the skin, which is the same number twice in two unrelated diseases. The eye programme is where the real variation lives, and it is a variation of route. One study ran an Elamipretide Topical Ophthalmic Solution in Fuchs' Corneal Endothelial Dystrophy (FCED), a disorder of the cornea. A separate phase 3 study used Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration. A 2025 review of eye delivery lists elamipretide among approaches that have achieved FDA approval within the past five years or have advanced to Phase 3 development, and in eye disease it is the second. So the spread follows disease and route rather than any search for an optimum. No dose-finding study has been published in people without one of these diagnoses. That is the study that would have to exist before any of these figures meant much outside the illness it was tested in.

Study	Amount	How often	Length
Placebo-controlled trial	40 mg	Once daily	24 weeks
Extension study	40 mg	Once daily	A further 168 weeks

SS-31 protocols in the published literature